CERIVASTATINE
Cerivastatin inhibits HMG‑CoA reductase to lower LDL cholesterol but was withdrawn due to rhabdomyolysis risk. Side effects included muscle toxicity and liver enzyme elevation.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
Cerivastatin is a potent HMG‑CoA reductase inhibitor (statin class), blocking the rate‑limiting step in cholesterol biosynthesis. By inhibiting conversion of HMG‑CoA to mevalonate, it reduces intracellular cholesterol, upregulates LDL receptors, lowers serum LDL, and influences downstream isoprenoid‑mediated signalling pathways affecting inflammation, endothelial function and cellular apoptosis.
Benefits and Advantages
Used in cholesterol‑biosynthesis pathway research, statin SAR modelling, cardiovascular‑risk biomarker studies, mitochondrial toxicity modelling, rhabdomyolysis‑mechanism studies, and mevalonate‑pathway signalling investigations.
Side Effects and Risks
Risks include severe rhabdomyolysis (notably dose‑dependent), hepatotoxicity, renal failure secondary to myolysis, neuropathy and drug–drug interactions via CYP inhibition. Handle with statin‑class bioactivity precautions.
Datasheet
| Molecular Formula | C26H34FNO5 |
|---|---|
| Molecular Weight | 459.5 g/mol |
| CAS Number | 145599-86-6 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Highly solubility |
| Purity | Purity information is available upon request (COA). |
| Synonym | cerivastatin; 145599-86-6; Lipobay; Cerivastatina; AM91H2KS67 |
| IUPAC/Chemical Name | (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)-3-pyridinyl]-3,5-dihydroxyhept-6-enoic acid |
| InChl Key | SEERZIQQUAZTOL-ANMDKAQQSA-N |
| InChl Code | InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
